目的 評(píng)價(jià)南京地區(qū)2017—2019年乳腺癌內(nèi)分泌治療藥物的臨床應(yīng)用情況和變化趨勢。方法 對南京地區(qū)41家醫(yī)療機(jī)構(gòu)2017—2019年乳腺癌內(nèi)分泌治療藥物的品種、銷售金額、用藥頻度（DDDs）等進(jìn)行統(tǒng)計(jì)和分析。結(jié)果 乳腺癌內(nèi)分泌治療藥物的銷售總金額和年DDDs逐年增長，平均年增長率分別為12.22%和13.89%。戈舍瑞林、亮丙瑞林、阿那曲唑等藥物連續(xù)3年排在銷售金額前3位，且占總銷售金額的70%左右。他莫昔芬、來曲唑、戈舍瑞林等藥物連續(xù)3年排在DDDs值前3位，且超過總DDDs值的50%。其中氟維司群的增長最為顯著。結(jié)論 南京乳腺癌內(nèi)分泌治療藥物床應(yīng)用廣泛，使用量和金額均穩(wěn)步增長，絕大部分藥物的DDC呈降低趨勢。

Objective To evaluate the clinical application and trends of endocrine therapy drugs for breast cancer in Nanjing area from 2017 to 2019. Methods Statistics and analysis of endocrine therapy drugs for breast cancer, sales amount and frequency of drug use (DDDs) were carried out in 41 hospitals in Nanjing area from 2017 to 2019. Results The total sales and DDDs of endocrine therapy drugs for breast cancer increased year by year, with an average annual growth rate of 12.22% and 13.89%, respectively. The drugs of goserelin, leuprorelin, and anastrozole were ranked in the top 3 of the sales amount and the total sales amount was about 70%, while tamoxifen, letrozole, and goserelinwere ranked in the top 3 of the DDDs, and the total DDDs ratio exceeded 50%. Fulvestran increased most significantly. Conclusion The endocrine therapydrugs for breast cancer are widely used in Nanjing area, both the usage and the amount are showing in a steadily growth trend, while the daily drug cost (DDC) of most drugs is in a decreasing trend.

R979.1

江蘇省軟科學(xué)研究項(xiàng)目（BR2020043）；南京大學(xué)醫(yī)院管理研究所管理項(xiàng)目課題（NDYG2019006）；中國藥學(xué)會(huì)科技開發(fā)中心科普項(xiàng)目（CMEI2020KPYJ（JZX）00412）